Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions.

Autor:	Colombo MG; Research and Clinical Center, Department of Medicine, Humanitas Hospital, Rozzano 20089, MI, Italy. massimo.colombo@humanitas.it., Musabaev EI; Research Institute of Virology, Scientific Research Institute of Virology, Tashkent 100194, Uzbekistan., Ismailov UY; Hepatoсenter, Research Institute of Virology, Scientific Research Institute of Virology, Tashkent 100194, Uzbekistan., Zaytsev IA; Department of Therapy, Infectious Diseases and Dermatology, Bogomolets National Medical University, Kyiv 01601, Ukraine., Nersesov AV; Department of Gastroenterology and Hepatology, National Research Institute of Cardiology and Internal Diseases, Almaty 050000, Kazakhstan., Anastasiy IA; Department Infectious Diseases, Bogomolets National Medical University, Kyiv 01601, Ukraine., Karpov IA; Department Infectious Diseases, Belarus State Medical University, Minsk 220116, Belarus., Golubovska OA; Department Infectious Diseases, Bogomolets National Medical University, Kyiv 01601, Ukraine., Kaliaskarova KS; Hepatology, Ministry of Health, Astana 010000, Kazakhstan., Ac R; Medical Affairs, Mylan Pharmaceuticals Private Limited, Kadubeesanahalli, Bengaluru 560103, India., Hadigal S; Medical Affairs, Mylan Pharmaceuticals Private Limited, Kadubeesanahalli, Bengaluru 560103, India.
Jazyk:	angličtina
Zdroj:	World journal of gastroenterology [World J Gastroenterol] 2019 Aug 07; Vol. 25 (29), pp. 3897-3919.
DOI:	10.3748/wjg.v25.i29.3897
Abstrakt:	Globally, 69.6 million individuals were infected with hepatitis C virus (HCV) infection in 2016. Of the six major HCV genotypes (GT), the most predominant one is GT1, worldwide. The prevalence of HCV in Central Asia, which includes most of the Commonwealth of Independent States (CIS), has been estimated to be 5.8% of the total global burden. The predominant genotype in the CIS and Ukraine regions has been reported to be GT1, followed by GT3. Inadequate HCV epidemiological data, multiple socio-economic barriers, and the lack of region-specific guidelines have impeded the optimal management of HCV infection in this region. In this regard, a panel of regional experts in the field of hepatology convened to discuss and provide recommendations on the diagnosis, treatment, and pre-, on-, and posttreatment assessment of chronic HCV infection and to ensure the optimal use of cost-effective antiviral regimens in the region. A comprehensive evaluation of the literature along with expert recommendations for the management of GT1-GT6 HCV infection with the antiviral agents available in the region has been provided in this review. This consensus document will help guide clinical decision-making during the management of HCV infection, further optimizing treatment outcomes in these regions. Competing Interests: Conflict-of-interest statement: Colombo MG received grants/research/clinical trial support from Bristol-Meyers Squibb [Hepatology, viral hepatitis C (Daclatasvir)], Gilead Sciences [Hepatology, viral hepatitis C (Sofosbuvir)], and Merck [Hepatology, viral hepatitis C (Boceprevir)]. Colombo MG is a part of the speaker’s bureau at Bayer, Gilead Sciences, and Roche and is a consultant and advisory panel at Bayer, AbbVie, Gilead Sciences, Janssen, Merck, Roche, Mylan, and Boehringer Ingelheim. Nersesov AV supports research at Janssen, Merck, AbbVie, Abbott, and Sanofi. Nersesov AV is a part of the speaker’s bureau at Abbott, AbbVie, Bayer, Gilead Sciences, Janssen, Merck, Roche, and Sanofi and is a board member/advisory panel at Abbott, AbbVie, Gilead Sciences, Janssen, Merck, Roche, and Mylan. Ravishankar AC and Hadigal S are employees at Mylan Pharmaceuticals Private Limited. The remaining authors have no conflict of interests.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu